top of page
Is your mAb optimized for
Cutting edge, viscosity-reduction technology for
This patented platform technology uses GRAS excipients to enable innovator mAbs and biosimilars for SubQ delivery, optimized dosing and enhanced market acceptance.
Proof of concept for your mAb in
8 Weeks !
bottom of page